The UIC team used protein engineering to design “a new biologic compound that tries to maximize the therapeutic effects of the enzyme while reducing toxicity and harmful responses in the patient,” according to a Jan. 28 news release from the university.
The compound destroyed leukemia cells in mice and shrank melanoma and liver cancer tumors in laboratory models, the release said. The group hopes to bring the compound to clinical trials.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
